Generex Biotechnology Corporation Signs $1.5 Million Insulin Deal with S Korea’s Dong Sung Pharmaceuticals

TORONTO, Aug 25 (Reuters) - Generex Biotechnology Corp signed a licensing agreement with one of South Korea's biggest drug companies, allowing its oral insulin spray to be sold in the country, which has one of the highest rates of diabetes.